1.78

10.56% 0.17

After Hours: 1.79 0.01 +0.56%

Milestone Pharmaceuticals Inc (MIST)

Overview News Price History Option Chain Financials Discussions Forecast

Milestone Pharmaceuticals Inc stock is traded at $1.78, with a volume of 3.33M. It is up +10.56% in the last 24 hours and up +12.66% over the past month. Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

Previous Close:

$1.61

Open:

$1.67

24h Volume:

3.33M

Relative Volume:

1.45

Market Cap:

$209.45M

Revenue:

$1.55M

Net Income/Loss:

$-63.06M

P/E Ratio:

-2.2365

EPS:

-0.7959

Net Cash Flow:

$-49.45M

1W Performance:

+35.88%

1M Performance:

+12.66%

6M Performance:

-11.00%

1Y Performance:

+172.63%

1-Day Range:

$1.61

$1.80

1-Week Range:

$1.245

$1.80

52-Week Range:

$0.63

$3.06

Milestone Pharmaceuticals Inc Stock (MIST) Company Profile

Name

Milestone Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (624)

Phone

(514) 336-0444

Address

1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC

Employee

Twitter

@MilestonePharma

Next Earnings Date

2026-03-20

Latest SEC Filings

MIST's Discussions on Twitter

Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIST Milestone Pharmaceuticals Inc	1.78	189.44M	1.55M	-63.06M	-49.45M	-0.7959
VRTX Vertex Pharmaceuticals Inc	443.92	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	775.53	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	785.07	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	327.25	42.63B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.19	33.72B	5.36B	287.73M	924.18M	2.5229

Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-25	Upgrade	TD Cowen	Hold → Buy
Sep-11-25	Initiated	Wells Fargo	Overweight
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Jun-20-23	Downgrade	Jefferies	Buy → Hold
Apr-22-22	Upgrade	Piper Sandler	Neutral → Overweight
Mar-05-21	Initiated	H.C. Wainwright	Buy
Jul-29-20	Upgrade	Oppenheimer	Perform → Outperform
Jul-24-20	Upgrade	Jefferies	Hold → Buy
Mar-25-20	Downgrade	Jefferies	Buy → Hold
Mar-24-20	Downgrade	Oppenheimer	Outperform → Perform
Mar-24-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-04-19	Initiated	Oppenheimer	Outperform
Jun-03-19	Initiated	Cowen	Outperform
Jun-03-19	Initiated	Jefferies	Buy
Jun-03-19	Initiated	Piper Jaffray	Overweight

View All

Milestone Pharmaceuticals Inc Stock (MIST) Latest News

Apr 07, 2026

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget

Apr 07, 2026

Apr 06, 2026

Will Freshworks Inc. stock benefit from sector rotationWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 06, 2026

Apr 04, 2026

Buybacks Report: Does Milestone Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Scalable Portfolio Growth Methods - baoquankhu1.vn

Apr 04, 2026

Apr 02, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 02, 2026

Institution Moves: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2026 Earnings Impact & Free Community Consensus Stock Picks - baoquankhu1.vn

Apr 02, 2026

MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill

Apr 02, 2026

Trails Edge Capital Partners, LP Acquires 5,333,333 Shares in Mi - GuruFocus

Apr 02, 2026

Mar 31, 2026

Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - Bitget

Mar 31, 2026

Milestone Pharmaceuticals (MIST) Secures Formulary Inclusion for Cardamyst - GuruFocus

Mar 31, 2026

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - The Manila Times

Mar 31, 2026

Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan

Mar 31, 2026

Mar 30, 2026

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 30, 2026

Mar 29, 2026

Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN

Mar 29, 2026

Mar 28, 2026

Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Mar 28, 2026

Mar 27, 2026

Published on: 2026-03-28 09:41:33 - baoquankhu1.vn

Mar 27, 2026

Published on: 2026-03-28 10:15:13 - baoquankhu1.vn

Mar 27, 2026

Milestone Pharmaceuticals Stock: Trails Edge Discloses 4.3% Stake Amid Q4 Earnings Anticipation - AD HOC NEWS

Mar 27, 2026

Mar 26, 2026

Trails Edge files amended 4.3% stake disclosure in Milestone Pharmaceuticals (MIST) - Stock Titan

Mar 26, 2026

Aug Chart Watch: Is Milestone Pharmaceuticals Incs ROIC above industry averageForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn

Mar 26, 2026

Mar 24, 2026

Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals - Markets Mojo

Mar 24, 2026

Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday - MarketBeat

Mar 24, 2026

Mar 23, 2026